TG Therapeutics Inc. (NASDAQ:TGTX) shot up 4.7% during trading on Thursday . The company traded as high as $5.74 and last traded at $5.75, with a volume of 254,438 shares trading hands. The stock had previously closed at $5.49.

A number of brokerages have commented on TGTX. Roth Capital reiterated a “buy” rating and set a $33.00 target price on shares of TG Therapeutics in a report on Wednesday. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a report on Monday, June 13th. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 10th. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, May 31st. Finally, SunTrust Banks Inc. initiated coverage on TG Therapeutics in a report on Friday, May 27th. They set a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $22.75.

The stock has a 50 day moving average of $5.98 and a 200-day moving average of $7.82. The firm’s market cap is $327.28 million.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. On average, equities analysts expect that TG Therapeutics Inc. will post ($1.23) EPS for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund boosted its stake in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned about 0.43% of TG Therapeutics worth $2,671,000 at the end of the most recent reporting period.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.